Bevacizumab Treatment and Retinal Vessel Monitoring

• Status: Completed
• Trial end date: 2009-04-01
• Target enrollment: 0
• Participant gender: All

Summary

Bevacizumab might influence the dynamic vessel function after being administered intravenously.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Technische Universität Dresden
• Treatments: Bevacizumab

Criteria

Inclusion Criteria:

• patients who wish and need bevacizumab treatment for underlying disease

Exclusion Criteria:

• previous bevacizumab treatment

• known eye disease, eye surgery or eye trauma in history

• myopia >-2.0 dpt

• hyperopia > +2.0 dpt.

• relevant media opacity of the lens

• acute heart disease, ischemic insult, proven coronary heart disease

• cardiac arrhythmia or vessel anomalies

• seizure disorder or episode in history

• migraine

• treatment with corticosteroids within 4 weeks before study inclusion

• intake of vasoactive drugs like AT-1 or glitazone

• pregnancy